% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Shapiro:282966,
      author       = {Shapiro, Noah L and Jones, Peter Simon and Mak, Elijah and
                      Tsvetanov, Kamen A and Goddard, Julia and Vontobel, Davi S
                      and Durcan, Robert and Chouliaras, Leonidas and Fryer, Tim
                      and Hong, Young T and Aigbirhio, Franklin and Heslegrave,
                      Amanda and Franzmeier, Nicolai and Brendel, Matthias and
                      Zetterberg, Henrik and O'Brien, John T and Rowe, James B and
                      Malpetti, Maura},
      title        = {{I}nflammation {PET} and plasma neurofilament light predict
                      survival in people with progressive supranuclear palsy.},
      journal      = {Brain communications},
      volume       = {7},
      number       = {6},
      issn         = {2632-1297},
      address      = {[Oxford]},
      publisher    = {Oxford University Press},
      reportid     = {DZNE-2025-01418},
      pages        = {fcaf467},
      year         = {2025},
      abstract     = {Progressive supranuclear palsy (PSP) is a primary tauopathy
                      characterized by atrophy and neuroinflammation of the
                      brainstem, the basal ganglia and, to a lesser degree, the
                      cortex. This study investigates the association of regional
                      atrophy (structural MRI), neuroinflammation ([11C]-PK11195
                      PET), peripheral markers of neurodegeneration [plasma
                      neurofilament light chain (NfL)] and clinical severity [PSP
                      rating scale (PSPRS)] with survival in people with PSP.
                      Fifty-nine people with PSP underwent longitudinal structural
                      MRI, surviving on average 3.2 years from the first scan (MRI
                      cohort). Sixteen participants (PET cohort) within this
                      cohort underwent cross-sectional [11C]-PK11195 PET and blood
                      sampling for plasma NfL. We applied modality-specific
                      principal component analyses on imaging data and ran partial
                      correlations, multivariate regressions and Bayesian models
                      to evaluate the association between survival and imaging
                      patterns, clinical severity and plasma NfL. In the PET
                      cohort, higher levels of localized inflammation in
                      subcortical regions [rho = -0.49, P = 0.02, Bayes factor
                      (BF) = 8.07] and plasma NfL (rho = -0.57, P = 0.01, BF =
                      4.63) were associated with shorter survival, while PSPRS
                      scores were not significant predictors of survival.
                      Subcortical atrophy was associated with shorter survival in
                      the larger cohort (r = -0.38, P = 0.001; β = -0.66, P =
                      0.001). Spearman's correlations, multivariate regressions
                      and Bayesian models converged to the same results. Regional
                      subcortical atrophy is a robust biomarker associated with
                      survival in people with PSP that can be utilized in
                      large-scale clinical trials. Translocator protein (TSPO) PET
                      and plasma NfL offer promising complementary markers for
                      smaller-scale trials, where they may prove more sensitive
                      than clinical scores or structural MRI alone. By linking
                      neuroinflammation to survival, our results also highlight
                      immunotherapy as a promising avenue for disease-modifying
                      treatment in PSP.},
      keywords     = {PET NfL (Other) / neuroinflammation (Other) / progressive
                      supranuclear palsy (Other) / survival (Other)},
      cin          = {AG Haass},
      ddc          = {610},
      cid          = {I:(DE-2719)1110007},
      pnm          = {352 - Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41416250},
      pmc          = {pmc:PMC12709281},
      doi          = {10.1093/braincomms/fcaf467},
      url          = {https://pub.dzne.de/record/282966},
}